These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8494784)

  • 1. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.
    Reisman D; Elkind NB; Roy B; Beamon J; Rotter V
    Cell Growth Differ; 1993 Feb; 4(2):57-65. PubMed ID: 8494784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs.
    Tobias KE; Shor J; Kahana C
    Oncogene; 1995 Nov; 11(9):1721-7. PubMed ID: 7478599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Position and orientation independent transactivation by c-Myc.
    Packham G; Bello-Fernandez C; Cleveland JL
    Cell Mol Biol Res; 1994; 40(7-8):699-706. PubMed ID: 7787888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R; Chen JM; Huard S; Wang E
    J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1.
    Rozenfeld-Granot G; Krishnamurthy J; Kannan K; Toren A; Amariglio N; Givol D; Rechavi G
    Oncogene; 2002 Feb; 21(10):1469-76. PubMed ID: 11896574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.
    Kirch HC; Flaswinkel S; Rumpf H; Brockmann D; Esche H
    Oncogene; 1999 Apr; 18(17):2728-38. PubMed ID: 10348347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z; Ge L; Wang M; Carr BI
    J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hnRNP U interacts with the c-Myc-Max complex on the E-box promoter region inducing the ornithine decarboxylase gene.
    Matsuoka Y; Uehara N; Tsubura A
    Oncol Rep; 2009 Aug; 22(2):249-55. PubMed ID: 19578763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Specific activity of the promoter containing Myc-Max response elements in c-myc-overexpressing cells].
    Zhang L; Liu T; Cui Q
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):923-6. PubMed ID: 11715508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
    Min S; Mascarenhas NT; Taparowsky EJ
    Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.
    Strauss BE; Shivakumar C; Deb SP; Deb S; Haas M
    Biochem Biophys Res Commun; 1995 Dec; 217(3):825-31. PubMed ID: 8554604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
    Yang W; Shen J; Wu M; Arsura M; FitzGerald M; Suldan Z; Kim DW; Hofmann CS; Pianetti S; Romieu-Mourez R; Freedman LP; Sonenshein GE
    Oncogene; 2001 Mar; 20(14):1688-702. PubMed ID: 11313917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
    Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
    Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV; Das GC
    Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mad4 is regulated by a transcriptional repressor complex that contains Miz-1 and c-Myc.
    Kime L; Wright SC
    Biochem J; 2003 Feb; 370(Pt 1):291-8. PubMed ID: 12418961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.
    Zhang D; Cao D; Russell R; Pizzorno G
    Cancer Res; 2001 Sep; 61(18):6899-905. PubMed ID: 11559567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.